{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T04:11:45Z","timestamp":1771906305561,"version":"3.50.1"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03206-1","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T10:00:41Z","timestamp":1766743241000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Engineered pluronic nanomicelles containing ATRA and sodium butyrate for selective TNBC differentiation therapy"],"prefix":"10.1007","volume":"43","author":[{"given":"Abolfazl","family":"Doustmihan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Jaymand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marziyeh","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana Jahanban","family":"Esfahlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"3206_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022;66:15\u201323.","journal-title":"Breast"},{"key":"3206_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4137\/BCBCR.S7707","volume":"5","author":"RJ Esfahlan","year":"2011","unstructured":"Esfahlan RJ, Zarghami N, Esfahlan AJ, Mollazadeh M, Nejati K, Nasiri M. The possible impact of obesity on androgen, progesterone and Estrogen receptors (ERalpha and ERbeta) gene expression in breast cancer patients. Breast Cancer Basic Clin Res. 2011;5:227\u201337.","journal-title":"Breast Cancer Basic Clin Res"},{"issue":"3","key":"3206_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.stem.2011.07.003","volume":"9","author":"P Zou","year":"2011","unstructured":"Zou P, Yoshihara H, Hosokawa K, Tai I, Shinmyozu K, Tsukahara F, et al. P57Kip2 and p27Kip1 cooperate to maintain hematopoietic stem cell quiescence through interactions with Hsc70. Cell Stem Cell. 2011;9(3):247\u201361.","journal-title":"Cell Stem Cell"},{"issue":"6","key":"3206_CR4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10616-012-9452-3","volume":"64","author":"K Nejati-Koshki","year":"2012","unstructured":"Nejati-Koshki K, Zarghami N, Pourhassan-Moghaddam M, Rahmati-Yamchi M, Mollazade M, Nasiri M, et al. Inhibition of leptin gene expression and secretion by silibinin: possible role of Estrogen receptors. Cytotechnology. 2012;64(6):719\u201326.","journal-title":"Cytotechnology"},{"issue":"3","key":"3206_CR5","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","volume":"35","author":"Y-Z Jiang","year":"2019","unstructured":"Jiang Y-Z, Ma D, Suo C, Shi J, Xue M, Hu X, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019;35(3):428\u201340. e5.","journal-title":"Cancer Cell"},{"key":"3206_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.101626","volume":"31","author":"S Karimi","year":"2025","unstructured":"Karimi S, Bakhshali R, Bolandi S, Zahed Z, Mojtaba Zadeh SS, Kaveh Zenjanab M, et al. For and against tumor microenvironment: Nanoparticle-based strategies for active cancer therapy. Mater Today Bio. 2025;31:101626.","journal-title":"Mater Today Bio"},{"issue":"11","key":"3206_CR7","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.molmed.2006.09.004","volume":"12","author":"F Yehiely","year":"2006","unstructured":"Yehiely F, Moyano JV, Evans JR, Nielsen TO, Cryns VL. Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med. 2006;12(11):537\u201344.","journal-title":"Trends Mol Med"},{"key":"3206_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jconrel.2018.08.043","volume":"288","author":"H Dianat-Moghadam","year":"2018","unstructured":"Dianat-Moghadam H, Heydarifard M, Jahanban-Esfahlan R, Panahi Y, Hamishehkar H, Pouremamali F, et al. Cancer stem cells-emanated therapy resistance: implications for liposomal drug delivery systems. J Control Release. 2018;288:62\u201383.","journal-title":"J Control Release"},{"key":"3206_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jconrel.2023.09.029","volume":"363","author":"A Doustmihan","year":"2023","unstructured":"Doustmihan A, Fathi M, Mazloomi M, Salemi A, Hamblin MR, Jahanban-Esfahlan R. Molecular targets, therapeutic agents and multitasking nanoparticles to deal with cancer stem cells: a narrative review. J Control Release. 2023;363:57\u201383.","journal-title":"J Control Release"},{"issue":"8","key":"3206_CR10","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.3390\/cancers11081207","volume":"11","author":"R Jahanban-Esfahlan","year":"2019","unstructured":"Jahanban-Esfahlan R, Seidi K, Manjili MH, Jahanban-Esfahlan A, Javaheri T, Zare P. Tumor cell dormancy: threat or opportunity in the fight against cancer. Cancers. 2019;11(8):1207.","journal-title":"Cancers"},{"key":"3206_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajps.2025.101036","author":"M Mazloomi","year":"2025","unstructured":"Mazloomi M, Doustmihan A, Alimohammadvand S, Hamishehkar H, Hamblin MR, Esfahlan RJ. Advanced drug delivery platforms target cancer stem cells. Asian J Pharm Sci. 2025. https:\/\/doi.org\/10.1016\/j.ajps.2025.101036.","journal-title":"Asian J Pharm Sci"},{"key":"3206_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.132940","volume":"272","author":"H Mahmudi","year":"2024","unstructured":"Mahmudi H, Shahpouri M, Adili-Aghdam MA, Akbari M, Salemi A, Alimohammadvand S, et al. Self-activating chitosan-based nanoparticles for sphingosin-1 phosphate modulator delivery and selective tumor therapy. Int J Biol Macromol. 2024;272:132940.","journal-title":"Int J Biol Macromol"},{"key":"3206_CR13","doi-asserted-by":"publisher","DOI":"10.34172\/apb.2024.054","author":"MAA-A Mohammad Shahpouri","year":"2024","unstructured":"Mohammad Shahpouri MAA-A, Mahmudi H, Ghiasvand S, Dadashi H, Salemi A, Alimohammadvand S, Roshangar L. Abolfazl Barzegari, Mehdi Jaymand, Rana Jahanban-Esfahlan. Dual-stage acting dendrimeric nanoparticle for deepened chemotherapeutic drug delivery to tumor cells. Adv Pharm Bull. 2024. https:\/\/doi.org\/10.34172\/apb.2024.054.","journal-title":"Adv Pharm Bull"},{"key":"3206_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10911-010-9165-1","volume":"15","author":"J Veeck","year":"2010","unstructured":"Veeck J, Esteller M. Breast cancer epigenetics: from DNA methylation to MicroRNAs. J Mammary Gland Biol Neoplasia. 2010;15:5\u201317.","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"3206_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.dnarep.2018.04.002","volume":"66\u201367","author":"M Majidinia","year":"2018","unstructured":"Majidinia M, Darband SG, Kaviani M, Nabavi SM, Jahanban-Esfahlan R, Yousefi B. Cross-regulation between Notch signaling pathway and MiRNA machinery in cancer. DNA Repair. 2018;66\u201367:30\u201341.","journal-title":"DNA Repair"},{"issue":"2","key":"3206_CR16","first-page":"233","volume":"11","author":"A Mehrgou","year":"2021","unstructured":"Mehrgou A, Ebadollahi S, Seidi K, Ayoubi-Joshaghani MH, Ahmadieh Yazdi A, Zare P, et al. Roles of MiRNAs in colorectal cancer: therapeutic implications and clinical opportunities. Adv Pharm Bull. 2021;11(2):233\u201347.","journal-title":"Adv Pharm Bull"},{"issue":"6880","key":"3206_CR17","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/416552a","volume":"416","author":"I Rhee","year":"2002","unstructured":"Rhee I, Bachman KE, Park BH, Jair K-W, Yen R-WC, Schuebel KE, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature. 2002;416(6880):552\u20136.","journal-title":"Nature"},{"issue":"1","key":"3206_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.molonc.2007.01.001","volume":"1","author":"S Ropero","year":"2007","unstructured":"Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2007;1(1):19\u201325.","journal-title":"Mol Oncol"},{"issue":"2","key":"3206_CR19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.bbcan.2016.04.001","volume":"1865","author":"A Kazanets","year":"2016","unstructured":"Kazanets A, Shorstova T, Hilmi K, Marques M, Witcher M. Epigenetic silencing of tumor suppressor genes: paradigms, puzzles, and potential. Biochim Et Biophys Acta (BBA)-Reviews Cancer. 2016;1865(2):275\u201388.","journal-title":"Biochim Et Biophys Acta (BBA)-Reviews Cancer"},{"issue":"2","key":"3206_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nrc1799","volume":"6","author":"SB Baylin","year":"2006","unstructured":"Baylin SB, Ohm JE. Epigenetic gene silencing in cancer\u2013a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 2006;6(2):107\u201316.","journal-title":"Nat Rev Cancer"},{"key":"3206_CR21","unstructured":"Diss E, Nalabothula N, Nguyen D, Chang E, Kwok Y, Carrier F. VorinostatSAHA promotes hyper-radiosensitivity in wild type p53 human glioblastoma cells. J Clin Oncol Res. 2014;2(1)."},{"issue":"15","key":"3206_CR22","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/jnci\/92.15.1210","volume":"92","author":"PA Marks","year":"2000","unstructured":"Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 2000;92(15):1210\u20136.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"3206_CR23","first-page":"1139","volume":"13","author":"P Rocchi","year":"2005","unstructured":"Rocchi P, Tonelli R, Camerin C, Purgato S, Fronza R, Bianucci F, et al. p21Waf1\/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Oncol Rep. 2005;13(6):1139\u201344.","journal-title":"Oncol Rep"},{"issue":"1","key":"3206_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrd1930","volume":"5","author":"CB Yoo","year":"2006","unstructured":"Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006;5(1):37\u201350.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"3206_CR25","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1634\/theoncologist.10-3-176","volume":"10","author":"E Kaminskas","year":"2005","unstructured":"Kaminskas E, Farrell AT, Wang Y-C, Sridhara R, Pazdur R. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza\u2122) for injectable suspension. Oncologist. 2005;10(3):176\u201382.","journal-title":"Oncologist"},{"issue":"6990","key":"3206_CR26","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nature02625","volume":"429","author":"G Egger","year":"2004","unstructured":"Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429(6990):457\u201363.","journal-title":"Nature"},{"issue":"9","key":"3206_CR27","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","volume":"5","author":"JE Bolden","year":"2006","unstructured":"Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5(9):769\u201384.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"3206_CR28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S1535-6108(03)00165-X","volume":"4","author":"RW Johnstone","year":"2003","unstructured":"Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell. 2003;4(1):13\u20138.","journal-title":"Cancer Cell"},{"issue":"196","key":"3206_CR29","first-page":"1","volume":"22","author":"MF Masoumeh Sharifi\u2011Azad","year":"2022","unstructured":"Masoumeh Sharifi\u2011Azad MF, Cho William C., Barzegari Abolfazl, Dadashi Hamed, Dadashpour Mehdi, Jahanban\u2011Esfahlan Rana. Recent advances in targeted drug delivery systems for resistant colorectal cancer. Cancer Cell Int. 2022;22(196):1\u201321.","journal-title":"Cancer Cell Int"},{"issue":"5","key":"3206_CR30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1200\/JCO.2010.32.1067","volume":"29","author":"MA Sanz","year":"2011","unstructured":"Sanz MA, Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol. 2011;29(5):495\u2013503.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3206_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.immuni.2011.07.002","volume":"35","author":"JA Hall","year":"2011","unstructured":"Hall JA, Grainger JR, Spencer SP, Belkaid Y. The role of retinoic acid in tolerance and immunity. Immunity. 2011;35(1):13\u201322.","journal-title":"Immunity"},{"issue":"20","key":"3206_CR32","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.4161\/cc.8.20.9761","volume":"8","author":"C Ginestier","year":"2009","unstructured":"Ginestier C, Wicinski J, Cervera N, Monville F, Finetti P, Bertucci F, et al. Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle. 2009;8(20):3297\u2013302.","journal-title":"Cell Cycle"},{"issue":"7","key":"3206_CR33","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-12-3175","volume":"19","author":"RM Connolly","year":"2013","unstructured":"Connolly RM, Nguyen NK, Sukumar S. Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment. Clin Cancer Res. 2013;19(7):1651\u20139.","journal-title":"Clin Cancer Res"},{"key":"3206_CR34","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1146\/annurev-pathol-011110-130303","volume":"6","author":"X-H Tang","year":"2011","unstructured":"Tang X-H, Gudas LJ. Retinoids, retinoic acid receptors, and cancer. Annu Rev Pathol. 2011;6:345\u201364.","journal-title":"Annu Rev Pathol"},{"issue":"22","key":"3206_CR35","doi-asserted-by":"publisher","first-page":"17149","DOI":"10.1074\/jbc.M000527200","volume":"275","author":"S-Y Sun","year":"2000","unstructured":"Sun S-Y, Wan H, Yue P, Hong WK, Lotan R. Evidence that retinoic acid receptor \u03b2 induction by retinoids is important for tumor cell growth inhibition. J Biol Chem. 2000;275(22):17149\u201353.","journal-title":"J Biol Chem"},{"issue":"12","key":"3206_CR36","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1038\/sj.onc.1203456","volume":"19","author":"SM Sirchia","year":"2000","unstructured":"Sirchia SM, Ferguson AT, Sironi E, Subramanyan S, Orlandi R, Sukumar S, et al. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor \u03b22 promoter in breast cancer cells. Oncogene. 2000;19(12):1556\u201363.","journal-title":"Oncogene"},{"issue":"10","key":"3206_CR37","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/jnci\/92.10.826","volume":"92","author":"M Widschwendter","year":"2000","unstructured":"Widschwendter M, Berger J, Hermann M, M\u00fcller HM, Amberger A, Zeschnigk M, et al. Methylation and Silencing of the retinoic acid receptor-\u03b22 gene in breast cancer. J Natl Cancer Inst. 2000;92(10):826\u201332.","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"3206_CR38","first-page":"2455","volume":"62","author":"SM Sirchia","year":"2002","unstructured":"Sirchia SM, Ren M, Pili R, Sironi E, Somenzi G, Ghidoni R, et al. Endogenous reactivation of the RAR\u03b22 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res. 2002;62(9):2455\u201361.","journal-title":"Cancer Res"},{"issue":"4","key":"3206_CR39","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1158\/1535-7163.MCT-06-0623","volume":"6","author":"M De los Santos","year":"2007","unstructured":"De los Santos M, Zambrano A, Aranda A. Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells. Mol Cancer Ther. 2007;6(4):1425\u201332.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"3206_CR40","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1080\/01635580802008278","volume":"60","author":"CC Spurling","year":"2008","unstructured":"Spurling CC, Suhl JA, Boucher N, Nelson CE, Rosenberg DW, Giardina C. The short chain fatty acid butyrate induces promoter demethylation and reactivation of RAR\u03b22 in colon cancer cells. Nutr Cancer. 2008;60(5):692\u2013702.","journal-title":"Nutr Cancer"},{"issue":"2","key":"3206_CR41","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1365-2036.2007.03562.x","volume":"27","author":"HM Hamer","year":"2008","unstructured":"Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost F, Brummer RJ. The role of butyrate on colonic function. Aliment Pharmacol Ther. 2008;27(2):104\u201319.","journal-title":"Aliment Pharmacol Ther"},{"key":"3206_CR42","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1146\/annurev.nutr.28.061807.155354","volume":"28","author":"B Delage","year":"2008","unstructured":"Delage B, Dashwood RH. Dietary manipulation of histone structure and function. Annu Rev Nutr. 2008;28:347\u201366.","journal-title":"Annu Rev Nutr"},{"issue":"8","key":"3206_CR43","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jnutbio.2011.04.010","volume":"23","author":"A de Conti","year":"2012","unstructured":"de Conti A, Kuroiwa-Trzmielina J, Horst MA, Bassoli BK, Chagas CE, Purgatto E, et al. Chemopreventive effects of the dietary histone deacetylase inhibitor tributyrin alone or in combination with vitamin A during the promotion phase of rat hepatocarcinogenesis. J Nutr Biochem. 2012;23(8):860\u20136.","journal-title":"J Nutr Biochem"},{"issue":"9","key":"3206_CR44","first-page":"2723","volume":"31","author":"S Sarkar","year":"2011","unstructured":"Sarkar S, Abujamra AL, Loew JE, Forman LW, Perrine SP, Faller DV. Histone deacetylase inhibitors reverse CpG methylation by regulating DNMT1 through ERK signaling. Anticancer Res. 2011;31(9):2723\u201332.","journal-title":"Anticancer Res"},{"issue":"18","key":"3206_CR45","doi-asserted-by":"publisher","first-page":"4172","DOI":"10.1200\/JCO.2005.07.114","volume":"23","author":"N Aass","year":"2005","unstructured":"Aass N, De Mulder PH, Mickisch GH, Mulders P, Van Oosterom AT, Van Poppel H, et al. Randomized phase II\/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol. 2005;23(18):4172\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3206_CR46","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1182\/blood.V79.2.299.299","volume":"79","author":"J Muindi","year":"1992","unstructured":"Muindi J, Frankel SR, Miller WH Jr, Jakubowski A, Scheinberg DA, Young CW, et al. Continuous treatment with all-transretinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid resistance in patients with acute promyelocytic leukemia. Blood. 1992;79(2):299\u2013303.","journal-title":"Blood"},{"issue":"2","key":"3206_CR47","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0003-9861(91)90482-X","volume":"287","author":"EZ Szuts","year":"1991","unstructured":"Szuts EZ, Harosi FI. Solubility of retinoids in water. Arch Biochem Biophys. 1991;287(2):297\u2013304.","journal-title":"Arch Biochem Biophys"},{"issue":"3","key":"3206_CR48","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/0009-8981(89)90231-3","volume":"181","author":"P Daniel","year":"1989","unstructured":"Daniel P, Brazier M, Cerutti I, Pieri F, Tardivel I, Desmet G, et al. Pharmacokinetic study of butyric acid administered in vivo as sodium and arginine butyrate salts. Clin Chim Acta. 1989;181(3):255\u201363.","journal-title":"Clin Chim Acta"},{"issue":"22","key":"3206_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228473","volume":"21","author":"MT Cambria","year":"2020","unstructured":"Cambria MT, Villaggio G, Laudani S, Pulvirenti L, Federico C, Saccone S, et al. The interplay between Fe3O4 superparamagnetic nanoparticles, sodium butyrate, and folic acid for intracellular transport. Int J Mol Sci. 2020;21(22):8473.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3206_CR50","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.bionut.2011.09.003","volume":"1","author":"N Krishnakumar","year":"2011","unstructured":"Krishnakumar N, Sulfikkarali N, RajendraPrasad N, Karthikeyan S. Enhanced anticancer activity of naringenin-loaded nanoparticles in human cervical (HeLa) cancer cells. Biomed Prev Nutr. 2011;1(4):223\u201331.","journal-title":"Biomed Prev Nutr"},{"key":"3206_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.101727","volume":"32","author":"M Pourbakhsh","year":"2025","unstructured":"Pourbakhsh M, Jabraili M, Akbari M, Jaymand M, Jahanban Esfahlan R. Poloxamer-based drug delivery systems: frontiers for treatment of solid tumors. Mater Today Bio. 2025;32:101727.","journal-title":"Mater Today Bio"},{"issue":"1","key":"3206_CR52","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s11033-025-10462-x","volume":"52","author":"A Faraji-Barhagh","year":"2025","unstructured":"Faraji-Barhagh A, Jahandar-Lashaki S, Esfahlan RJ, Alizadeh E. Current nano drug delivery systems for targeting head and neck squamous cell carcinoma microenvironment: a narrative review. Mol Biol Rep. 2025;52(1):369.","journal-title":"Mol Biol Rep"},{"issue":"10","key":"3206_CR53","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1039\/C4PY00039K","volume":"5","author":"A Pitto-Barry","year":"2014","unstructured":"Pitto-Barry A, Barry NP. Pluronic\u00ae block-copolymers in medicine: from chemical and biological versatility to rationalisation and clinical advances. Polym Chem. 2014;5(10):3291\u20137.","journal-title":"Polym Chem"},{"key":"3206_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.matdes.2025.115098","author":"A Doustmihan","year":"2025","unstructured":"Doustmihan A, Akbari M, Jaymand M, Liu G, Esfahlan RJ. Micelleplex nucleic acid delivery systems: overcoming barriers for treatment of advanced solid tumors. Mater Des. 2025. https:\/\/doi.org\/10.1016\/j.matdes.2025.115098.","journal-title":"Mater Des"},{"issue":"6","key":"3206_CR55","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1080\/1061186X.2017.1289538","volume":"25","author":"L-Y Zhao","year":"2017","unstructured":"Zhao L-Y, Zhang W-M. Recent progress in drug delivery of pluronic P123: pharmaceutical perspectives. J Drug Target. 2017;25(6):471\u201384.","journal-title":"J Drug Target"},{"key":"3206_CR56","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ijpharm.2018.11.064","volume":"556","author":"NU Khaliq","year":"2019","unstructured":"Khaliq NU, Park DY, Yun BM, Jung YW, Seo JH, Hwang CS, et al. Pluronics: intelligent building units for targeted cancer therapy and molecular imaging. Int J Pharm. 2019;556:30\u201344.","journal-title":"Int J Pharm"},{"key":"3206_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.145647","author":"M Lotfi","year":"2025","unstructured":"Lotfi M, Nakhlband A, Doustmihan A, Omidi Y, Fathi M, Adibkia K. Formulation and evaluation of in-situ forming poloxamer-based hydrogel containing thiolated chitosan nanoparticles as intranasal galantamine delivery system. Int J Biol Macromol. 2025. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.145647.","journal-title":"Int J Biol Macromol"},{"issue":"7","key":"3206_CR58","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/jps.10397","volume":"92","author":"ML Adams","year":"2003","unstructured":"Adams ML, Lavasanifar A, Kwon GS. Amphiphilic block copolymers for drug delivery. J Pharm Sci. 2003;92(7):1343\u201355.","journal-title":"J Pharm Sci"},{"key":"3206_CR59","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.biomaterials.2015.01.014","volume":"48","author":"B Xiao","year":"2015","unstructured":"Xiao B, Zhang M, Viennois E, Zhang Y, Wei N, Baker MT, et al. Inhibition of MDR1 gene expression and enhancing cellular uptake for effective colon cancer treatment using dual-surface-functionalized nanoparticles. Biomaterials. 2015;48:147\u201360.","journal-title":"Biomaterials"},{"issue":"1","key":"3206_CR60","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jconrel.2009.09.026","volume":"142","author":"DY Alakhova","year":"2010","unstructured":"Alakhova DY, Rapoport NY, Batrakova EV, Timoshin AA, Li S, Nicholls D, et al. Differential metabolic responses to pluronic in MDR and non-MDR cells: a novel pathway for chemosensitization of drug resistant cancers. J Control Release. 2010;142(1):89\u2013100.","journal-title":"J Control Release"},{"issue":"12","key":"3206_CR61","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.3390\/molecules26123610","volume":"26","author":"J Yu","year":"2021","unstructured":"Yu J, Qiu H, Yin S, Wang H, Li Y. Polymeric drug delivery system based on pluronics for cancer treatment. Molecules. 2021;26(12):3610.","journal-title":"Molecules"},{"issue":"11","key":"3206_CR62","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1016\/j.biomaterials.2010.12.039","volume":"32","author":"W Zhang","year":"2011","unstructured":"Zhang W, Shi Y, Chen Y, Ye J, Sha X, Fang X. Multifunctional pluronic P123\/F127 mixed polymeric micelles loaded with Paclitaxel for the treatment of multidrug resistant tumors. Biomaterials. 2011;32(11):2894\u2013906.","journal-title":"Biomaterials"},{"key":"3206_CR63","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.msec.2018.10.092","volume":"96","author":"X Yang","year":"2019","unstructured":"Yang X, Yu Y, Huang X, Chen Q, Wu H, Wang R, et al. Delivery of platinum (II) drugs with bulky ligands in trans-geometry for overcoming cisplatin drug resistance. Mater Sci Engineering: C. 2019;96:96\u2013104.","journal-title":"Mater Sci Engineering: C"},{"issue":"64","key":"3206_CR64","doi-asserted-by":"publisher","first-page":"ra642","DOI":"10.1126\/scitranslmed.3001385","volume":"3","author":"M Murakami","year":"2011","unstructured":"Murakami M, Cabral H, Matsumoto Y, Wu S, Kano MR, Yamori T, et al. Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting. Sci Transl Med. 2011;3(64):ra642\u20132.","journal-title":"Sci Transl Med"},{"issue":"4","key":"3206_CR65","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1021\/bc300632w","volume":"24","author":"X Wei","year":"2013","unstructured":"Wei X, Senanayake TH, Warren G, Vinogradov SV. Hyaluronic acid-based nanogel\u2013drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors. Bioconjug Chem. 2013;24(4):658\u201368.","journal-title":"Bioconjug Chem"},{"key":"3206_CR66","doi-asserted-by":"crossref","unstructured":"Tinoco LMS, Silva FLOd, Ferreira LAM, Leite EA, Carneiro G. Hyaluronic acid-coated nanoemulsions loaded with a hydrophobic ion pair of all-trans retinoic acid for improving the anticancer activity. Brazilian J Pharm Sci. 2019;54:1\u201310.","DOI":"10.1590\/s2175-97902018000417361"},{"issue":"9","key":"3206_CR67","doi-asserted-by":"publisher","first-page":"10875","DOI":"10.1021\/acsomega.3c09782","volume":"9","author":"M Kaveh Zenjanab","year":"2024","unstructured":"Kaveh Zenjanab M, Abdolahinia ED, Alizadeh E, Hamishehkar H, Shahbazi R, Ranjbar-Navazi Z, et al. Hyaluronic acid-targeted niosomes for effective breast cancer chemostarvation therapy. ACS Omega. 2024;9(9):10875\u201385.","journal-title":"ACS Omega"},{"key":"3206_CR68","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jconrel.2020.03.033","volume":"322","author":"S Bhattacharya","year":"2020","unstructured":"Bhattacharya S, Ghosh A, Maiti S, Ahir M, Debnath GH, Gupta P, et al. Delivery of thymoquinone through hyaluronic acid-decorated mixed Pluronic\u00ae nanoparticles to attenuate angiogenesis and metastasis of triple-negative breast cancer. J Control Release. 2020;322:357\u201374.","journal-title":"J Control Release"},{"issue":"41","key":"3206_CR69","doi-asserted-by":"publisher","first-page":"24507","DOI":"10.1039\/D0RA03207G","volume":"10","author":"P Li","year":"2020","unstructured":"Li P, Dai X, Qu L, Sui Y, Zhang C. Dual responsive oligo (lysine)-modified pluronic F127 hydrogels for drug release of 5-fluorouracil. RSC Adv. 2020;10(41):24507\u201314.","journal-title":"RSC Adv"},{"issue":"3","key":"3206_CR70","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3390\/gels8030182","volume":"8","author":"V Malytskyi","year":"2022","unstructured":"Malytskyi V, Moreau J, Callewaert M, Henoumont C, Cadiou C, Feuillie C, et al. Synthesis and characterization of conjugated hyaluronic acids. Application to stability studies of chitosan-hyaluronic acid nanogels based on fluorescence resonance energy transfer. Gels. 2022;8(3):182.","journal-title":"Gels"},{"issue":"25","key":"3206_CR71","doi-asserted-by":"publisher","first-page":"5934","DOI":"10.1016\/j.biomaterials.2011.04.075","volume":"32","author":"W Zhang","year":"2011","unstructured":"Zhang W, Shi Y, Chen Y, Hao J, Sha X, Fang X. The potential of pluronic polymeric micelles encapsulated with Paclitaxel for the treatment of melanoma using subcutaneous and pulmonary metastatic mice models. Biomaterials. 2011;32(25):5934\u201344.","journal-title":"Biomaterials"},{"issue":"7","key":"3206_CR72","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s12032-025-02796-0","volume":"42","author":"Z Hashemi","year":"2025","unstructured":"Hashemi Z, Kaveh Zenjanab M, Pourbakhsh M, Doustmihan A, Fathi M, Jahanban Esfahlan R. Hyaluronic acid-modified theranostic niosomes for targeted Fingolimod delivery and inhibition of triple-negative breast cancer metastasis. Med Oncol. 2025;42(7):256.","journal-title":"Med Oncol"},{"key":"3206_CR73","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jconrel.2016.06.017","volume":"235","author":"S Bhattacharjee","year":"2016","unstructured":"Bhattacharjee S. DLS and zeta potential\u2013what they are and what they are not? J Control Release. 2016;235:337\u201351.","journal-title":"J Control Release"},{"issue":"9","key":"3206_CR74","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.micron.2012.04.003","volume":"43","author":"SA Wight","year":"2012","unstructured":"Wight SA, Konicek AR. Electron scattering cross section measurements in a variable pressure scanning electron microscope. Micron. 2012;43(9):985\u201391.","journal-title":"Micron"},{"key":"3206_CR75","doi-asserted-by":"crossref","unstructured":"Stuart BH. Infrared spectroscopy: fundamentals and applications. Wiley; 2004.","DOI":"10.1002\/0470011149"},{"key":"3206_CR76","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.biomaterials.2015.01.007","volume":"51","author":"S Bhattacharya","year":"2015","unstructured":"Bhattacharya S, Ahir M, Patra P, Mukherjee S, Ghosh S, Mazumdar M, et al. PEGylated-thymoquinone-nanoparticle mediated retardation of breast cancer cell migration by deregulation of cytoskeletal actin polymerization through miR-34a. Biomaterials. 2015;51:91\u2013107.","journal-title":"Biomaterials"},{"issue":"5","key":"3206_CR77","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1093\/jnci\/51.5.1409","volume":"51","author":"HD Soule","year":"1973","unstructured":"Soule HD, Vazquez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst. 1973;51(5):1409\u201316.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"3206_CR78","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.nano.2010.11.004","volume":"7","author":"T Lei","year":"2011","unstructured":"Lei T, Srinivasan S, Tang Y, Manchanda R, Nagesetti A, Fernandez-Fernandez A, et al. Comparing cellular uptake and cytotoxicity of targeted drug carriers in cancer cell lines with different drug resistance mechanisms. Nanomedicine Nanotechnol Biol Med. 2011;7(3):324\u201332.","journal-title":"Nanomedicine Nanotechnol Biol Med"},{"issue":"5","key":"3206_CR79","doi-asserted-by":"publisher","first-page":"055015","DOI":"10.1088\/1748-605X\/ad5d9b","volume":"19","author":"M Sharifi-Azad","year":"2024","unstructured":"Sharifi-Azad M, Kaveh Zenjanab M, Shahpouri M, Adili-Aghdam MA, Fathi M, Jahanban-Esfahlan R. Codelivery of methotrexate and Silibinin by niosome nanoparticles for enhanced chemotherapy of CT26 colon cancer cells. Biomed Mater. 2024;19(5):055015.","journal-title":"Biomed Mater"},{"issue":"1","key":"3206_CR80","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11033-025-10241-8","volume":"52","author":"M Fakeri","year":"2025","unstructured":"Fakeri M, Haghi M, Jahanban Esfahlan R, Fathi M, Hosseinpour Feizi MA. Targeted apoptosis in breast cancer cells via niosome-mediated delivery of cyclophosphamide and sodium oxamate. Mol Biol Rep. 2025;52(1):139.","journal-title":"Mol Biol Rep"},{"issue":"1\u20132","key":"3206_CR81","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1\u20132):55\u201363.","journal-title":"J Immunol Methods"},{"issue":"2","key":"3206_CR82","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nprot.2007.30","volume":"2","author":"C-C Liang","year":"2007","unstructured":"Liang C-C, Park AY, Guan J-L. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007;2(2):329\u201333.","journal-title":"Nat Protoc"},{"issue":"1","key":"3206_CR83","doi-asserted-by":"publisher","DOI":"10.1002\/biot.201700417","volume":"13","author":"EC Costa","year":"2018","unstructured":"Costa EC, de Melo-Diogo D, Moreira AF, Carvalho MP, Correia IJ. Spheroids formation on non\u2010adhesive surfaces by liquid overlay technique: considerations and practical approaches. Biotechnol J. 2018;13(1):1700417.","journal-title":"Biotechnol J"},{"key":"3206_CR84","doi-asserted-by":"crossref","unstructured":"Dadashi H, Mashinchian M, Karimian-Shaddel A, Mohabbat A, Vandghanooni S, Eskandani M et al. Chitosan nanoparticles loaded with Metformin and Digoxin synergistically inhibit MCF-7 breast cancer cells through suppression of NOTCH-1 and HIF-1\u03b1 gene expression. Int J Biol Macromol. 2024:138418.","DOI":"10.1016\/j.ijbiomac.2024.138418"},{"issue":"4","key":"3206_CR85","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2009\u2013 \u2206\u2206CT method. Methods. 2001;25(4):402\u20138.","journal-title":"Methods"},{"issue":"1","key":"3206_CR86","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0022-1759(95)00072-I","volume":"184","author":"I Vermes","year":"1995","unstructured":"Vermes I, Haanen C, Steffens-Nakken H, Reutellingsperger C. A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 1995;184(1):39\u201351.","journal-title":"J Immunol Methods"},{"issue":"22","key":"3206_CR87","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1038\/onc.2016.467","volume":"36","author":"M Wu","year":"2017","unstructured":"Wu M, Kim M, Chen Y, Yang J, Chang C. Retinoic acid directs breast cancer cell state changes through regulation of TET2-PKC\u03b6 pathway. Oncogene. 2017;36(22):3193\u2013206.","journal-title":"Oncogene"},{"issue":"1","key":"3206_CR88","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.molonc.2014.07.010","volume":"9","author":"P Marcato","year":"2015","unstructured":"Marcato P, Dean CA, Liu R-Z, Coyle KM, Bydoun M, Wallace M, et al. Aldehyde dehydrogenase 1A3 influences breast cancer progression via differential retinoic acid signaling. Mol Oncol. 2015;9(1):17\u201331.","journal-title":"Mol Oncol"},{"issue":"1","key":"3206_CR89","doi-asserted-by":"publisher","first-page":"7047","DOI":"10.1038\/s41598-018-25526-1","volume":"8","author":"B Mezquita","year":"2018","unstructured":"Mezquita B, Mezquita P, Pau M, Gasa L, Navarro L, Samitier M, et al. All-trans-retinoic acid activates the pro-invasive Src-YAP-Interleukin 6 axis in triple-negative MDA-MB-231 breast cancer cells while cerivastatin reverses this action. Sci Rep. 2018;8(1):7047.","journal-title":"Sci Rep"},{"key":"3206_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-018-0975-0","volume":"37","author":"V Ciccone","year":"2018","unstructured":"Ciccone V, Terzuoli E, Donnini S, Giachetti A, Morbidelli L, Ziche M. Stemness marker ALDH1A1 promotes tumor angiogenesis via retinoic acid\/HIF-1\u03b1\/VEGF signalling in MCF-7 breast cancer cells. J Exp Clin Cancer Res. 2018;37:1\u201316.","journal-title":"J Exp Clin Cancer Res"},{"key":"3206_CR91","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3389\/fphar.2019.00447","volume":"10","author":"Y-H Zhu","year":"2019","unstructured":"Zhu Y-H, Ye N, Tang X-F, Khan MI, Liu H-L, Shi N, et al. Synergistic effect of retinoic acid polymeric micelles and prodrug for the pharmacodynamic evaluation of tumor suppression. Front Pharmacol. 2019;10:447.","journal-title":"Front Pharmacol"},{"issue":"21","key":"3206_CR92","first-page":"5464","volume":"59","author":"M Nacht","year":"1999","unstructured":"Nacht M, Ferguson AT, Zhang W, Petroziello JM, Cook BP, Gao YH, et al. Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res. 1999;59(21):5464\u201370.","journal-title":"Cancer Res"},{"issue":"7","key":"3206_CR93","first-page":"2586","volume":"100","author":"S C\u00f4t\u00e9","year":"2002","unstructured":"C\u00f4t\u00e9 S, Rosenauer A, Bianchini A, Seiter K, Vandewiele J, Nervi C, et al. Response to histone deacetylase Inhibition of novel PML\/RAR\u03b1 mutants detected in retinoic acid\u2013resistant APL cells. Blood. J Am Soc Hematol. 2002;100(7):2586\u201396.","journal-title":"J Am Soc Hematol"},{"issue":"9","key":"3206_CR94","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1172\/JCI200111537","volume":"108","author":"L-Z He","year":"2001","unstructured":"He L-Z, Tolentino T, Grayson P, Zhong S, Warrell RP, Rifkind RA, et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest. 2001;108(9):1321\u201330.","journal-title":"J Clin Invest"},{"issue":"21","key":"3206_CR95","doi-asserted-by":"publisher","first-page":"11295","DOI":"10.1073\/pnas.94.21.11295","volume":"94","author":"S Minucci","year":"1997","unstructured":"Minucci S, Horn V, Bhattacharyya N, Russanova V, Ogryzko VV, Gabriele L, et al. A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells. Proc Natl Acad Sci USA. 1997;94(21):11295\u2013300.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"21","key":"3206_CR96","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1093\/jnci\/90.21.1621","volume":"90","author":"JrRP Warrell","year":"1998","unstructured":"Warrell Jr RP, He L-Z, Richon V, Calleja E, Pandolfi PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst. 1998;90(21):1621\u20135.","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"3206_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/natrevmats.2016.71","volume":"1","author":"J Li","year":"2016","unstructured":"Li J, Mooney DJ. Designing hydrogels for controlled drug delivery. Nat Rev Mater. 2016;1(12):1\u201317.","journal-title":"Nat Rev Mater"},{"issue":"1","key":"3206_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12896-025-01027-8","volume":"25","author":"R Ezati","year":"2025","unstructured":"Ezati R, Johari B, Seyf JY, Mortazavi Y, Azizi M, Samadian H. Anticancer effects of folic acid-functionalized covalent organic framework containing doxorubicin on SW480 colon cancer cells: a promising tool for drug targeted delivery. BMC Biotechnol. 2025;25(1):1\u201321.","journal-title":"BMC Biotechnol"},{"key":"3206_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124285","volume":"659","author":"N Asadi","year":"2024","unstructured":"Asadi N, Gharbavi M, Rezaeejam H, Farajollahi A, Johari B. Zinc nanoparticles coated with doxorubicin-conjugated alginate as a radiation sensitizer in triple-negative breast cancer cells. Int J Pharm. 2024;659:124285.","journal-title":"Int J Pharm"},{"issue":"5","key":"3206_CR100","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s42250-022-00425-1","volume":"5","author":"H Felenji","year":"2022","unstructured":"Felenji H, Johari B, Moradi M, Gharbavi M, Danafar H. Folic acid-conjugated iron oxide magnetic nanoparticles based on bovine serum albumin (BSA) for targeted delivery of Curcumin to suppress liver cancer cells. Chem Afr. 2022;5(5):1627\u201339.","journal-title":"Chem Afr"},{"issue":"5","key":"3206_CR101","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1016\/j.msec.2013.02.036","volume":"33","author":"Y-Y Li","year":"2013","unstructured":"Li Y-Y, Li L, Dong H-Q, Cai X-J, Ren T-B. Pluronic F127 nanomicelles engineered with nuclear localized functionality for targeted drug delivery. Mater Sci Engineering: C. 2013;33(5):2698\u2013707.","journal-title":"Mater Sci Engineering: C"},{"issue":"24","key":"3206_CR102","doi-asserted-by":"publisher","first-page":"10819","DOI":"10.7314\/APJCP.2014.15.24.10819","volume":"15","author":"B Wang","year":"2015","unstructured":"Wang B, Yan Y-W, Zhou Q, Gui S-Y, Chen F-H, Wang Y. A novel all-trans retinoid acid derivative induces apoptosis in MDA-MB-231 breast cancer cells. Asian Pac J Cancer Prev. 2015;15(24):10819\u201324.","journal-title":"Asian Pac J Cancer Prev"},{"key":"3206_CR103","doi-asserted-by":"publisher","unstructured":"Elnozahi NA, Abd ELAziz EA, Helmy MW, Bistawroos AE. Modulatory effect of sodium butyrate on anticancer activity of abemaciclib in MDA-MB-231 human breast cancer cells. 2022. https:\/\/doi.org\/10.21203\/RS.3.RS-1619486\/V1","DOI":"10.21203\/RS.3.RS-1619486\/V1"},{"issue":"1","key":"3206_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-017-0593-4","volume":"16","author":"V Salimi","year":"2017","unstructured":"Salimi V, Shahsavari Z, Safizadeh B, Hosseini A, Khademian N, Tavakoli-Yaraki M. Sodium butyrate promotes apoptosis in breast cancer cells through reactive oxygen species (ROS) formation and mitochondrial impairment. Lipids Health Dis. 2017;16(1):1\u201311.","journal-title":"Lipids Health Dis"},{"issue":"5","key":"3206_CR105","doi-asserted-by":"publisher","first-page":"8181","DOI":"10.3390\/molecules20058181","volume":"20","author":"ES Al-Sheddi","year":"2015","unstructured":"Al-Sheddi ES, Al-Oqail MM, Saquib Q, Siddiqui MA, Musarrat J, Al-Khedhairy AA, et al. Novel all trans-retinoic acid derivatives: cytotoxicity, inhibition of cell cycle progression and induction of apoptosis in human cancer cell lines. Molecules. 2015;20(5):8181\u201397.","journal-title":"Molecules"},{"key":"3206_CR106","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S249756","author":"Z Huang","year":"2020","unstructured":"Huang Z, Yu P, Tang J. Characterization of triple-negative breast cancer MDA-MB-231 cell spheroid model. Onco Targets Ther. 2020. https:\/\/doi.org\/10.2147\/OTT.S249756.","journal-title":"Onco Targets Ther"},{"key":"3206_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01543","volume":"10","author":"DP Saraiva","year":"2020","unstructured":"Saraiva DP, Matias AT, Braga S, Jacinto A, Cabral MG. Establishment of a 3D co-culture with MDA-MB-231 breast cancer cell line and patient-derived immune cells for application in the development of immunotherapies. Front Oncol. 2020;10:1543.","journal-title":"Front Oncol"},{"issue":"15","key":"3206_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155400","volume":"21","author":"L Pulze","year":"2020","unstructured":"Pulze L, Congiu T, Brevini TA, Grimaldi A, Tettamanti G, D\u2019antona P, et al. MCF7 spheroid development: new insight about spatio\/temporal arrangements of TNTs, amyloid fibrils, cell connections, and cellular bridges. Int J Mol Sci. 2020;21(15):5400.","journal-title":"Int J Mol Sci"},{"key":"3206_CR109","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1339251","volume":"12","author":"LH Chong","year":"2024","unstructured":"Chong LH, Yip AK, Farm HJ, Mahmoud LN, Zeng Y, Chiam K-H. The role of cell-matrix adhesion and cell migration in breast tumor growth and progression. Front Cell Dev Biol. 2024;12:1339251.","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"3206_CR110","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.stem.2007.08.014","volume":"1","author":"C Ginestier","year":"2007","unstructured":"Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1(5):555\u201367.","journal-title":"Cell Stem Cell"},{"issue":"6","key":"3206_CR111","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.2353\/ajpath.2007.070535","volume":"171","author":"A Ouhtit","year":"2007","unstructured":"Ouhtit A, Abd Elmageed ZY, Abdraboh ME, Lioe TF, Raj MH. In vivo evidence for the role of CD44s in promoting breast cancer metastasis to the liver. Am J Pathol. 2007;171(6):2033\u20139.","journal-title":"Am J Pathol"},{"key":"3206_CR112","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.3389\/fimmu.2020.01324","volume":"11","author":"S-S Yin","year":"2020","unstructured":"Yin S-S, Gao F-H. Molecular mechanism of tumor cell immune escape mediated by CD24\/Siglec-10. Front Immunol. 2020;11:1324.","journal-title":"Front Immunol"},{"issue":"1","key":"3206_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2022.113160","volume":"416","author":"M Sharma","year":"2022","unstructured":"Sharma M, Tollefsbol TO. Combinatorial epigenetic mechanisms of sulforaphane, genistein and sodium butyrate in breast cancer inhibition. Exp Cell Res. 2022;416(1):113160.","journal-title":"Exp Cell Res"},{"issue":"10","key":"3206_CR114","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1210\/me.2007-0151","volume":"21","author":"M De los Santos","year":"2007","unstructured":"De los Santos M, Zambrano A, S\u00e1nchez-Pacheco A, Aranda A. Histone deacetylase inhibitors regulate retinoic acid receptor \u03b2 expression in neuroblastoma cells by both transcriptional and posttranscriptional mechanisms. Mol Endocrinol. 2007;21(10):2416\u201326.","journal-title":"Mol Endocrinol"},{"issue":"12","key":"3206_CR115","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1158\/1078-0432.CCR-08-2786","volume":"15","author":"M Bots","year":"2009","unstructured":"Bots M, Johnstone RW. Rational combinations using HDAC inhibitors. Clin Cancer Res. 2009;15(12):3970\u20137.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3206_CR116","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41565-020-00793-0","volume":"16","author":"S Shen","year":"2021","unstructured":"Shen S, Xu X, Lin S, Zhang Y, Liu H, Zhang C, et al. A nanotherapeutic strategy to overcome chemotherapeutic resistance of cancer stem-like cells. Nat Nanotechnol. 2021;16(1):104\u201313.","journal-title":"Nat Nanotechnol"},{"issue":"18","key":"3206_CR117","doi-asserted-by":"publisher","first-page":"8607","DOI":"10.1039\/C5NR01084E","volume":"7","author":"K Hu","year":"2015","unstructured":"Hu K, Zhou H, Liu Y, Liu Z, Liu J, Tang J, et al. Hyaluronic acid functional amphipathic and redox-responsive polymer particles for the co-delivery of doxorubicin and cyclopamine to eradicate breast cancer cells and cancer stem cells. Nanoscale. 2015;7(18):8607\u201318.","journal-title":"Nanoscale"},{"issue":"7","key":"3206_CR118","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1158\/0008-5472.CAN-15-1619","volume":"76","author":"VF Merino","year":"2016","unstructured":"Merino VF, Nguyen N, Jin K, Sadik H, Cho S, Korangath P, et al. Combined treatment with epigenetic, differentiating, and chemotherapeutic agents cooperatively targets tumor-initiating cells in triple-negative breast cancer. Cancer Res. 2016;76(7):2013\u201324.","journal-title":"Cancer Res"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03206-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03206-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03206-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T18:02:51Z","timestamp":1770487371000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03206-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":118,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["3206"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03206-1","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"21 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"92"}}